AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference
AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”
Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (Letermovir) from AiCuris
Royalty Pharma and AiCuris have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time-payment of $220 million.
AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
AiCuris has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV)
AiCuris unterstützt das Land NRW bei der COVID-19 Ausbruchsbekämpfung in Schlachtbetrieben
An der Durchführung der ca. 20.000 Testung beteiligt sich AiCuris neben den vier Chemischen und Veterinäruntersuchungsämter des Landes.
AiCuris gets involved in the fight against Corona
“In times like these, biotech and pharmaceutical companies have a great societal responsibility”
AiCuris collaborates with myTomorrows to initiate an Early Access Program for Pritelivir
AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.